Spotlight on Internal Medicine
Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach
StartActivity Details
Expires: April 21, 2023
Provided By
This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.
Target Audience
Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
- Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
- Select IBD therapies based on risk stratification and guideline recommendations
Activity Description
Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.
Faculty
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY
Disclosure of Financial Relationships
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).
Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial
relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial
relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to
disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to
disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic
(Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to
disclose.
Naemat Sandhu, MD, has no financial relationships to
disclose.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations
accredited by ACCME.
Instructions for Receiving Credit
Fee Information
There is no fee for this educational activity.
Criteria for Success
In order to receive credit, participants must review the activity content and
successfully complete both the post-test and evaluation. A statement of
credit will be available to print immediately. You must score 75% or higher
on the post-test to receive credit for this activity. If you have questions
about this activity, please contact AGA Institute at
education@gastro.org.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random
drawing on a quarterly basis from among all eligible entries and
notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Activity Details
Expires: April 21, 2023
Provided By
This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.
Target Audience
Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
- Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
- Select IBD therapies based on risk stratification and guideline recommendations
Activity Description
Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.
Faculty
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY
Disclosure of Financial Relationships
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).
Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial
relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial
relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to
disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to
disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic
(Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to
disclose.
Naemat Sandhu, MD, has no financial relationships to
disclose.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations
accredited by ACCME.
Instructions for Receiving Credit
Fee Information
There is no fee for this educational activity.
Criteria for Success
In order to receive credit, participants must review the activity content and
successfully complete both the post-test and evaluation. A statement of
credit will be available to print immediately. You must score 75% or higher
on the post-test to receive credit for this activity. If you have questions
about this activity, please contact AGA Institute at
education@gastro.org.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random
drawing on a quarterly basis from among all eligible entries and
notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Internal Medicine Presentations
Challenging Cases of Severe COVID-19: Unlikely Patients and Breakthrough Infections
StartActivity Details
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: February 27, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess disease severity and implications in patients with COVID-19
- Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients
Activity Description
When we think of severe COVID-19 infection, we often do not think of the young and otherwise healthy. In this activity, an interprofessional panel of experts dive into discussion on some unlikely severe COVID-19 cases and breakthrough infections as submitted directly by clinicians from all over the country.
Chair
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA
Faculty
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant
financial relationships with ineligible companies to disclose.
Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).
Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: February 27, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess disease severity and implications in patients with COVID-19
- Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients
Activity Description
When we think of severe COVID-19 infection, we often do not think of the young and otherwise healthy. In this activity, an interprofessional panel of experts dive into discussion on some unlikely severe COVID-19 cases and breakthrough infections as submitted directly by clinicians from all over the country.
Chair
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA
Faculty
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant
financial relationships with ineligible companies to disclose.
Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).
Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 10: Weight Gain and Other Adverse Events
StartActivity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
Activity Description
As ART options continue to evolve, clinicians learn more about their adverse events. Recently, weight gain has come to the forefront and clinicians struggle to balance the impact of weight gain on patient health with efficacy of ART regimens. Dr. Richard A. Elion and Dr. Todd T. Brown discuss a patient who needs to switch regimens because of neuropsychiatric adverse events and is concerned about weight gain. Data about weight gain associated with certain ART regimens, risk factors for weight gain, impact on risk for cardiovascular disease, and strategies to balance the risk for neuropsychiatric adverse events and potential for weight gain when selecting a new ART regimen.
Faculty
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia
Professor of Medicine
Johns Hopkins University
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Todd T. Brown, MD, PhD: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions
Activity Description
As ART options continue to evolve, clinicians learn more about their adverse events. Recently, weight gain has come to the forefront and clinicians struggle to balance the impact of weight gain on patient health with efficacy of ART regimens. Dr. Richard A. Elion and Dr. Todd T. Brown discuss a patient who needs to switch regimens because of neuropsychiatric adverse events and is concerned about weight gain. Data about weight gain associated with certain ART regimens, risk factors for weight gain, impact on risk for cardiovascular disease, and strategies to balance the risk for neuropsychiatric adverse events and potential for weight gain when selecting a new ART regimen.
Faculty
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia
Professor of Medicine
Johns Hopkins University
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Todd T. Brown, MD, PhD: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 11: Intersection of COVID-19 and HIV
StartActivity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder
Activity Description
As the COVID-19 pandemic continues to evolve, clinicians often have questions about special considerations for their patients with HIV, including details about anti-SARS-CoV-2 monoclonal antibodies, vaccines, and ART regimens. Dr. Sharon L. Walmsley and Dr. Karine Lacombe discuss a patient newly diagnosed with HIV who recently contracted COVID-19 and whether the patient is eligible for anti-SARS-CoV-2 monoclonal antibodies, timing of both COVID-19 and flu vaccinations, and how to initiate an ART regimen.
Faculty
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Associate Professor
Infectious and Tropical Diseases
Saint-Antoine Hospital
Professor
Sorbonne University Medical School
Paris, France
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare
Karine Lacombe, MD, PhD: Consulting Fees: Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Janssen Global Services, LLC, ViiV Healthcare Limited
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder
Activity Description
As the COVID-19 pandemic continues to evolve, clinicians often have questions about special considerations for their patients with HIV, including details about anti-SARS-CoV-2 monoclonal antibodies, vaccines, and ART regimens. Dr. Sharon L. Walmsley and Dr. Karine Lacombe discuss a patient newly diagnosed with HIV who recently contracted COVID-19 and whether the patient is eligible for anti-SARS-CoV-2 monoclonal antibodies, timing of both COVID-19 and flu vaccinations, and how to initiate an ART regimen.
Faculty
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Associate Professor
Infectious and Tropical Diseases
Saint-Antoine Hospital
Professor
Sorbonne University Medical School
Paris, France
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare
Karine Lacombe, MD, PhD: Consulting Fees: Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Janssen Global Services, LLC, ViiV Healthcare Limited
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 12: HIV and CVD
StartActivity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug–drug interactions
Activity Description
As patients with HIV continue to live longer, there is a greater concern of comorbidities typically seen in aging patients, such as cardiovascular disease (CVD). Patients with HIV have an increased risk of CVD and HIV specialists should feel prepared to address this risk with their patients and to tailor both ART and other medications. Dr. Sharon L. Walmsley and Dr. Priscilla Hsue discuss a patient with several risk factors for CVD, including the risk of CVD in HIV, the relationship between ART and CVD, drug–drug interactions, strategies to estimate risk, and initiating treatment for common risk factors, such as hypercholesterolemia.
Faculty
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Professor of Medicine
University of California San Francisco
Chief of the Division of Cardiology
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare
Priscilla Hsue, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc.; Contracted Research: Novartis International AG
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: February 9, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug–drug interactions
Activity Description
As patients with HIV continue to live longer, there is a greater concern of comorbidities typically seen in aging patients, such as cardiovascular disease (CVD). Patients with HIV have an increased risk of CVD and HIV specialists should feel prepared to address this risk with their patients and to tailor both ART and other medications. Dr. Sharon L. Walmsley and Dr. Priscilla Hsue discuss a patient with several risk factors for CVD, including the risk of CVD in HIV, the relationship between ART and CVD, drug–drug interactions, strategies to estimate risk, and initiating treatment for common risk factors, such as hypercholesterolemia.
Faculty
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada
Professor of Medicine
University of California San Francisco
Chief of the Division of Cardiology
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare
Priscilla Hsue, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc.; Contracted Research: Novartis International AG
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma
StartActivity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series – Module 8: Implicit Bias and Racial Disparities
StartActivity Details
0.25 Contact Hour(s)
Expires: January 14, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Incorporate strategies to improve equity in care across patient populations
Activity Description
Many patients of color face implicit bias or discrimination in health care, including HIV care. This can result in lower levels of adherence and viral suppression as well as a lack of equity in health care. It is important for clinicians to recognize their own biases and those that exist in their practice in order to provide equitable care for patients of color. Dr. David Malebranche and Dr. Oni Blackstock discuss a patient who has faced implicit bias and a lack of equity at another provider’s practice. They discuss the dangers of implicit bias, strategies to recognize it, opportunities to achieve equitable care, and both individual and clinic-level changes that can reduce implicit bias.
Faculty
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia
Founder and Executive Director
Health Justice
New York, New York
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.
Oni Blackstock, MD, MHS: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: January 14, 2023
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Incorporate strategies to improve equity in care across patient populations
Activity Description
Many patients of color face implicit bias or discrimination in health care, including HIV care. This can result in lower levels of adherence and viral suppression as well as a lack of equity in health care. It is important for clinicians to recognize their own biases and those that exist in their practice in order to provide equitable care for patients of color. Dr. David Malebranche and Dr. Oni Blackstock discuss a patient who has faced implicit bias and a lack of equity at another provider’s practice. They discuss the dangers of implicit bias, strategies to recognize it, opportunities to achieve equitable care, and both individual and clinic-level changes that can reduce implicit bias.
Faculty
Internal Medicine Physician
Sexual Health/HIV Expert
Atlanta, Georgia
Founder and Executive Director
Health Justice
New York, New York
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
David Malebranche, MD, MPH: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare Limited; Speakers’ Bureaus: Gilead Sciences, Inc.
Oni Blackstock, MD, MHS: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – Combining Patient-Centered Care for Major Depressive Disorder with the Latest Antidepressant Efficacy to Optimize Treatment Plans
StartActivity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Incorporate patient preferences, values, and goals when developing a care plan
- Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
- Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to optimizing MDD treatment plans, thus increasing the proportion
of patients with MDD who are able to achieve functional recovery.
Agenda
- Prevalence of major depressive disorder since COVID-19 pandemic
- Functional recovery and the importance of helping patients move beyond symptom remission
- Case study, functional recovery and shared decision-making
- Residual symptoms that frequently impede functional recovery
- Case study, residual symptoms
- Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery
Faculty
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.
Activity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Incorporate patient preferences, values, and goals when developing a care plan
- Evaluate patients being treated for MDD to identify the presence of residual symptoms, such as cognitive dysfunction
- Assess treatment strategies for a patient with MDD that will maximize their quality of life and functional recovery
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Only roughly half of patients with MDD achieve recovery after 6 months of treatment. The others continue to experience residual symptoms that impair their ability to function at work, school, and home. To ensure that more patients with MDD achieve functional recovery, clinicians require practical information about how to provide early, optimized care. In this activity, an expert faculty member will support learners as they are asked to track patients’ response to treatment and detect and manage common residual MDD symptoms. Two cases will be used to illustrate how to individualize MDD care to maximize patients’ chances of recovery.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to optimizing MDD treatment plans, thus increasing the proportion
of patients with MDD who are able to achieve functional recovery.
Agenda
- Prevalence of major depressive disorder since COVID-19 pandemic
- Functional recovery and the importance of helping patients move beyond symptom remission
- Case study, functional recovery and shared decision-making
- Residual symptoms that frequently impede functional recovery
- Case study, residual symptoms
- Strategies for managing residual symptoms and responding to insufficient progress toward functional recovery
Faculty
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, and (4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.
Paths to Functional Recovery in Major Depressive Disorder: Putting the Patient First – A Patient-Centered Approach to Preventing, Detecting, and Managing Adverse Effects of Antidepressants
StartActivity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Evaluate patients being treated for MDD to identify common adverse effects such as sexual dysfunction, weight gain, and sleep disturbance
- Assess treatment strategies for a patient with MDD who is experiencing an adverse effect on their current MDD therapy
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member will support learners as they are asked to respond to patients experiencing side effects related to their antidepressant use. Two cases will be used to illustrate how a patient-centered approach to MDD care can maximize treatment tolerability.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to preventing, detecting, and managing antidepressant side
effects, thus minimizing the impact of adverse effects on patients’
lives.
Agenda
- Prevalence of major antidepressant adverse effects
- Common adverse effects of antidepressants
- Case study, sexual dysfunction
- Case study, weight gain
- Antidepressant comparative tolerability
- Strategies for managing antidepressant adverse effects
Faculty
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest
Activity Details
0.5 Contact Hour(s)
Expires: January 25, 2023
Jointly Provided By
This activity is jointly provided by Medical Education Resources and CMEology.
Target Audience
Psychiatrists and advanced practice psychiatry clinicians who care for patients with major depressive disorder.
Learning Objectives
- Evaluate patients being treated for MDD to identify common adverse effects such as sexual dysfunction, weight gain, and sleep disturbance
- Assess treatment strategies for a patient with MDD who is experiencing an adverse effect on their current MDD therapy
Activity Description
This is one of two related online multimedia activities designed to assess and enhance clinical decision-making through immersive, interactive learning. Participants will use realistic “near-life” education as they make decisions for what comes next – just like real life.
Statement of Educational Need
Adverse effects associated with antidepressants are common. In addition to compromising patients’ health and quality of life, they are one of the most common reasons that individuals with MDD fail to adhere to their treatment plans. To minimize the impact of antidepressant side effects on the lives of patients with MDD, clinicians require education on how to prevent, detect, and manage the most common adverse effects caused by these medications. In this activity, an expert faculty member will support learners as they are asked to respond to patients experiencing side effects related to their antidepressant use. Two cases will be used to illustrate how a patient-centered approach to MDD care can maximize treatment tolerability.
Learning Goal/Purpose
The goal of this activity is to increase clinicians’ knowledge and competence
with regard to preventing, detecting, and managing antidepressant side
effects, thus minimizing the impact of adverse effects on patients’
lives.
Agenda
- Prevalence of major antidepressant adverse effects
- Common adverse effects of antidepressants
- Case study, sexual dysfunction
- Case study, weight gain
- Antidepressant comparative tolerability
- Strategies for managing antidepressant adverse effects
Faculty
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Advisory/Consultant: Acadia, Inc.; Akili, Inc.; Alkermes PLC;
Allergan, Inc. (Forest, Naurex); Clexio Biosciences, Ltd.; H. Lundbeck, A/S;
Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.;
Otsuka Pharmaceutical Company, Ltd.; Pfizer, Inc.; Seelos
Grant Support: Acadia, Inc.; Allergan, Inc.; Axsome Therapeutics
Inc.; Intracellular, Inc.; Johnson & Johnson (Janssen); Otsuka Pharmaceutical
Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI);
Takeda
Royalties: American Psychiatric Press; Guilford Publications; Herald
House; W.W. Norton & Company, Inc.; Wolters Kluwer
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Accreditation Statement
This
activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of
Medical Education Resources (MER) and CMEology. MER is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 0.5 contact hour(s) of continuing nursing education.
Instructions for Receiving Credit
There are no fees for participating in and receiving credit for this activity. During the period January 25, 2022 through January 25, 2023, participants must (1) read the learning objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest
Finding the Path in Eosinophilic Esophagitis: Interdisciplinary Strategies for Adult and Pediatric Patients
StartActivity Details
1.25 AANP contact hour(s)
Expires: December 10, 2022
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Target Audience
This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).
Program Overview
During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
- Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
- Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
- Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
- Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making
Faculty
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
Global Education Group and Integritas Communications. Global Education Group
is accredited by the American Association of Nurse Practitioners as an
approved provider of nurse practitioner continuing education. Provider
number: 110121. This activity is approved for 1.25 contact hour(s) (which
includes 0.0 hour(s) of pharmacology).
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Term of Offering
This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc.,
Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals
Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical
Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc,
Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire
plc, Takeda Pharmaceutical Company Limited.
Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir,
Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx,
Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS,
Meritage, Regeneron, Shire/Takeda.
Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
1.25 AANP contact hour(s)
Expires: December 10, 2022
Provided By
This activity is jointly provided by Global Education Group and Integritas Communications.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Target Audience
This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).
Program Overview
During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
- Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
- Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
- Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
- Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making
Faculty
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
Global Education Group and Integritas Communications. Global Education Group
is accredited by the American Association of Nurse Practitioners as an
approved provider of nurse practitioner continuing education. Provider
number: 110121. This activity is approved for 1.25 contact hour(s) (which
includes 0.0 hour(s) of pharmacology).
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Term of Offering
This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc.,
Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals
Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical
Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc,
Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire
plc, Takeda Pharmaceutical Company Limited.
Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir,
Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx,
Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS,
Meritage, Regeneron, Shire/Takeda.
Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 6: Neuropsychological and Cognitive Changes
StartActivity Details
0.25 Contact Hour(s)
Expires: December 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor antiretroviral therapy (ART) regimens according to patient comorbidities, risk factors, adverse events, and drug−drug interactions
Activity Description
Mental health comorbidities, particularly depression, are common in HIV. Clinicians who treat patients with HIV often lack experience in pharmacologic treatment of depression or other mental health disorders. Dr. Richard A. Elion and Dr. Glenn Jordan Treisman discuss a patient with worsening depression and chronic pain in terms of screening for her depression, the relationship between depression and chronic pain, and both nonpharmacologic and pharmacologic options to treat her depression.
Faculty
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Glenn Jordan Treisman, MD, PhD: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.
Activity Details
0.25 Contact Hour(s)
Expires: December 8, 2022
Provided By
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
Target Audience
The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.
Learning Objective
After completing this activity, the participant should be better able to:
- Tailor antiretroviral therapy (ART) regimens according to patient comorbidities, risk factors, adverse events, and drug−drug interactions
Activity Description
Mental health comorbidities, particularly depression, are common in HIV. Clinicians who treat patients with HIV often lack experience in pharmacologic treatment of depression or other mental health disorders. Dr. Richard A. Elion and Dr. Glenn Jordan Treisman discuss a patient with worsening depression and chronic pain in terms of screening for her depression, the relationship between depression and chronic pain, and both nonpharmacologic and pharmacologic options to treat her depression.
Faculty
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:
Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies
Glenn Jordan Treisman, MD, PhD: Nothing to disclose
The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine (PIM) and Integritas Communications.
PIM is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the health care team.
Designation of Credit
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.25 contact hour(s).
Instructions for Receiving Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM
via email at inquiries@pimed.com or
at http://www.pimed.com/.
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas
via email at info@exchangecme.com.